Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

NHS England Expands Loco-regional Treatment Options for Colorectal Cancer Patients with Metastatic Disease - NHS England will routinely commission Selective Internal Radiation Therapy (SIRT) for colorectal cancer patients with liver-limited metastatic disease who are refractory or intolerant to chemotherapy1 - TheraSphere.com / DCBead.com / BTG-IO.com
NHS England Expands Loco-regional Treatment Options for Colorectal Cancer Patients with Metastatic Disease

 

PRZOOM - /newswire/ - London, United Kingdom, 2019/02/05 - NHS England will routinely commission Selective Internal Radiation Therapy (SIRT) for colorectal cancer patients with liver-limited metastatic disease who are refractory or intolerant to chemotherapy1 - TheraSphere.com / DCBead.com / BTG-IO.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc, a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019, NHS England will routinely commission Selective Internal Radiation Therapy (SIRT) for colorectal cancer patients with liver-limited metastatic disease who are refractory or intolerant to chemotherapy.1

“This landmark decision covers Y90 SIRT with glass or resin microspheres and gives UK clinicians and patients increased access to loco-regional treatments from the metastatic colorectal cancer (mCRC) “toolbox” as described by the European Society for Medical Oncology (ESMO) in their mCRC treatment guidelines2”, said Rachel Duggan, Country Sales Manager, UK & Ireland. “Another option in that toolbox, TACE with Drug-Eluting Beads (DEBIRI with DC Bead®), is already funded in the UK”.

BTG offers comprehensive training and service support to centres wishing to initiate SIRT and/or DEBIRI programmes, including the clinical rationale, patient selection, and access to funding.

About TheraSphere®
TheraSphere® (therasphere.comis a targeted therapy that consists of millions of glass microspheres containing radioactive yttrium-90. The microspheres are delivered directly to liver tumours through the hepatic artery via catheter and become permanently lodged there. Because the procedure delivers the treatment directly to the liver tumour, the radiation destroys the tumour cells with minimal impact to the surrounding healthy liver tissue. The microspheres continue to deliver radiation to the tumour over the course of several weeks after treatment. Over 20,000 patients worldwide have been treated with TheraSphere®.

About DC Bead®
DC Bead® (dcbead.com) is a drug-eluting bead with CE Mark approval for loading with doxorubicin or irinotecan, providing an effective standardised liver-directed therapy for primary and metastatic liver cancer. With more than ten years’ clinical experience, extensive peer-review evidence supports the benefits offered by the unique chemistry of DC Bead®. In intermediate HCC, these benefits include improved tolerability and tumour response versus cTACE and high rates of five-year survival.3-7 In metastatic colorectal cancer patients, DC Bead® has been shown to offer improved survival and enhanced quality of life versus systemic chemotherapy alone.8

About BTG Interventional Oncology
BTG Interventional Oncology (btg-io.com) is committed to transforming the way cancer is treated with our portfolio of minimally-invasive, highly targeted cancer therapies that can be personalised to each patient’s needs. Our products are used to treat or provide symptomatic relief for people with cancer and benign tumours.

1. NHS England: Clinical Commissioning Policy: Selective internal radiation therapy (SIRT) for chemotherapy refractory / intolerant metastatic colorectal cancer (adults)
2. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016: 27:1386-1422
3. Lammer J et al. Cardiovasc Intervent Radiol 2010; 33: 41-52
4. Song MJ et al. Eur J Gastroenterol Hepatol 2011; 23: 521-7
5. Dhanasakeran R et al. J Surg Oncol 2010; 101: 476-80
6. Burrel M et al. J Hepatol 2012; 56: 1330-5
7. Malagari K et al. Cardiovasc Intervent Radiol 2012; 35: 1119-28
8. Fiorentini G et al. Anticancer Res 2012; 32: 1387.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


NHS England Expands Loco-regional Treatment Options for Colorectal Cancer Patients with Metastatic Disease

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
TheraSphere | BTG Interventional Oncolo
Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)77 7325 1178 (mobile) chris.sampson[.]btgplc.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  MONOVERSE USA, Inc.

Visit  JobsWare.com

Visit  Mokuyobi







 
  ©2021 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today